A Novel Inhibitor of Poly(ADP-Ribose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA Damage-Activated cGAS-STING Pathway
Loss-of-function mutations in the Breast Cancer Susceptibility Gene (BRCA1 and BRCA2) are often detected in patients with breast cancer. Poly(ADP-ribose) polymerase-1 (PARP1) plays a key role in the repair of DNA strand breaks, and PARP inhibitors have been shown to induce highly selective killing of BRCA1/2-deficient tumor cells, a mechanism termed synthetic lethality. In our previous study, a novel PARP1 inhibitor─(E)-2-(2,3-dibromo-4,5-dimethoxybenzylidene)-N-(4-fluorophenyl) hydrazine-1-carbothioamide (4F-DDC)─was synthesized, which significantly inhibited PARP1 activity with an IC50 value of 82 ± 9 nM. The current study aimed to explore the mechanism(s) underlying the antitumor activity of 4F-DDC under in vivo and in vitro conditions. 4F-DDC was found to selectively inhibit the proliferation of BRCA mutant cells, with highly potent effects on HCC-1937 (BRCA1-/-) cells. Furthermore, 4F-DDC was found to induce apoptosis and G2/M cell cycle arrest in HCC-1937 cells. Interestingly, immunofluorescence and Western blot results showed that 4F-DDC induced DNA double strand breaks and further activated the cGAS-STING pathway in HCC-1937 cells. In vivo analysis results revealed that 4F-DDC inhibited the growth of HCC-1937-derived tumor xenografts, possibly via the induction of DNA damage and activation of the cGAS-STING pathway. In summary, the current study provides a new perspective on the antitumor mechanism of PARP inhibitors and showcases the therapeutic potential of 4F-DDC in the treatment of breast cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
---|---|
Enthalten in: |
Chemical research in toxicology - 37(2024), 4 vom: 15. Apr., Seite 561-570 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jin, Yonglong [VerfasserIn] |
---|
Links: |
---|
Themen: |
9007-49-2 |
---|
Anmerkungen: |
Date Completed 16.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1021/acs.chemrestox.3c00343 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370237277 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370237277 | ||
003 | DE-627 | ||
005 | 20240416232837.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240328s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1021/acs.chemrestox.3c00343 |2 doi | |
028 | 5 | 2 | |a pubmed24n1377.xml |
035 | |a (DE-627)NLM370237277 | ||
035 | |a (NLM)38534178 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jin, Yonglong |e verfasserin |4 aut | |
245 | 1 | 2 | |a A Novel Inhibitor of Poly(ADP-Ribose) Polymerase-1 Inhibits Proliferation of a BRCA-Deficient Breast Cancer Cell Line via the DNA Damage-Activated cGAS-STING Pathway |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 16.04.2024 | ||
500 | |a Date Revised 16.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Loss-of-function mutations in the Breast Cancer Susceptibility Gene (BRCA1 and BRCA2) are often detected in patients with breast cancer. Poly(ADP-ribose) polymerase-1 (PARP1) plays a key role in the repair of DNA strand breaks, and PARP inhibitors have been shown to induce highly selective killing of BRCA1/2-deficient tumor cells, a mechanism termed synthetic lethality. In our previous study, a novel PARP1 inhibitor─(E)-2-(2,3-dibromo-4,5-dimethoxybenzylidene)-N-(4-fluorophenyl) hydrazine-1-carbothioamide (4F-DDC)─was synthesized, which significantly inhibited PARP1 activity with an IC50 value of 82 ± 9 nM. The current study aimed to explore the mechanism(s) underlying the antitumor activity of 4F-DDC under in vivo and in vitro conditions. 4F-DDC was found to selectively inhibit the proliferation of BRCA mutant cells, with highly potent effects on HCC-1937 (BRCA1-/-) cells. Furthermore, 4F-DDC was found to induce apoptosis and G2/M cell cycle arrest in HCC-1937 cells. Interestingly, immunofluorescence and Western blot results showed that 4F-DDC induced DNA double strand breaks and further activated the cGAS-STING pathway in HCC-1937 cells. In vivo analysis results revealed that 4F-DDC inhibited the growth of HCC-1937-derived tumor xenografts, possibly via the induction of DNA damage and activation of the cGAS-STING pathway. In summary, the current study provides a new perspective on the antitumor mechanism of PARP inhibitors and showcases the therapeutic potential of 4F-DDC in the treatment of breast cancer | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
650 | 7 | |a BRCA1 protein, human |2 NLM | |
650 | 7 | |a BRCA1 Protein |2 NLM | |
650 | 7 | |a Poly(ADP-ribose) Polymerases |2 NLM | |
650 | 7 | |a EC 2.4.2.30 |2 NLM | |
650 | 7 | |a BRCA2 protein, human |2 NLM | |
650 | 7 | |a BRCA2 Protein |2 NLM | |
650 | 7 | |a DNA |2 NLM | |
650 | 7 | |a 9007-49-2 |2 NLM | |
700 | 1 | |a Wang, Lijie |e verfasserin |4 aut | |
700 | 1 | |a Jin, Chengxue |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Na |e verfasserin |4 aut | |
700 | 1 | |a Shimizu, Shosei |e verfasserin |4 aut | |
700 | 1 | |a Xiao, Wenjing |e verfasserin |4 aut | |
700 | 1 | |a Guo, Chuanlong |e verfasserin |4 aut | |
700 | 1 | |a Liu, Xiguang |e verfasserin |4 aut | |
700 | 1 | |a Si, Hongzong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Chemical research in toxicology |d 1989 |g 37(2024), 4 vom: 15. Apr., Seite 561-570 |w (DE-627)NLM01260321X |x 1520-5010 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:561-570 |
856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.chemrestox.3c00343 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 37 |j 2024 |e 4 |b 15 |c 04 |h 561-570 |